busulfan has been researched along with Obesity in 9 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objective of this retrospective study was to determine the pharmacokinetic impact of using ideal body weight as the initial dosing weight in obese as compared to non-obese transplant recipients." | 5.51 | Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients. ( Griffin, SP; Hsu, JW; Murthy, HS; Richards, AI; Wheeler, SE; Wiggins, LE, 2019) |
| " Routine dosing on the basis of BSA or AIBW in adults and adolescents does not require a specific accommodation for the obese." | 5.30 | The impact of obesity and disease on busulfan oral clearance in adults. ( Appelbaum, FR; Corneau, B; Gibbs, JP; Gooley, T; Murray, G; Slattery, JT; Stewart, P, 1999) |
| " This IV form is expected to reduce the high pharmacokinetic variability exhibited with oral busulfan and as a result, to better target the plasma area under the curve (AUC)." | 2.72 | Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. ( Leger, F; Lennon, S; Nguyen, L; Puozzo, C, 2006) |
| " This article reviews the current published literature on the dosing of pharmacologic agents used for HCT preparative regimens with specific focus on the obese patient population." | 2.50 | Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. ( Bubalo, J; Carpenter, PA; Leather, HL; Majhail, N; Marks, DI; Perales, MA; Pidala, J; Savani, BN; Shaughnessy, P; Wingard, J, 2014) |
| " The objective of this retrospective study was to determine the pharmacokinetic impact of using ideal body weight as the initial dosing weight in obese as compared to non-obese transplant recipients." | 1.51 | Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients. ( Griffin, SP; Hsu, JW; Murthy, HS; Richards, AI; Wheeler, SE; Wiggins, LE, 2019) |
| " The prevalence of overweight and obese children has also increased in the pediatric cancer setting, causing substantial concern over proper chemotherapeutic dosing in this population." | 1.37 | Busulfan dosing in children with BMIs ≥ 85% undergoing HSCT: a new optimal strategy. ( Browning, B; Donaldson, A; Halverson, T; Kletzel, M; Shinkle, M; Thormann, K, 2011) |
| " Routine dosing on the basis of BSA or AIBW in adults and adolescents does not require a specific accommodation for the obese." | 1.30 | The impact of obesity and disease on busulfan oral clearance in adults. ( Appelbaum, FR; Corneau, B; Gibbs, JP; Gooley, T; Murray, G; Slattery, JT; Stewart, P, 1999) |
| "Busulfan was quantitated in plasma samples at 10 time points within the 6 h dosing interval using HPLC before and after dose numbers 1, 2, 5, 13 and 14." | 1.29 | Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? ( Blanz, J; Ehninger, G; Kühnle, A; Kumbier, I; Mewes, K; Proksch, B; Schroer, S; Schuler, U; Zeller, KP, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Simon, N | 1 |
| Coiteux, V | 1 |
| Bruno, B | 1 |
| Taque, S | 1 |
| Charbonnier, A | 1 |
| Souchet, L | 1 |
| Vincent, L | 1 |
| Yakoub-Agha, I | 1 |
| Chalandon, Y | 1 |
| Griffin, SP | 1 |
| Wheeler, SE | 1 |
| Wiggins, LE | 1 |
| Murthy, HS | 1 |
| Hsu, JW | 1 |
| Richards, AI | 1 |
| Bubalo, J | 1 |
| Carpenter, PA | 1 |
| Majhail, N | 1 |
| Perales, MA | 1 |
| Marks, DI | 1 |
| Shaughnessy, P | 1 |
| Pidala, J | 1 |
| Leather, HL | 1 |
| Wingard, J | 1 |
| Savani, BN | 1 |
| Hunter, MR | 1 |
| Sabo, RT | 1 |
| McCarty, JM | 1 |
| Newland, AM | 1 |
| Browning, B | 1 |
| Thormann, K | 1 |
| Donaldson, A | 1 |
| Halverson, T | 1 |
| Shinkle, M | 1 |
| Kletzel, M | 1 |
| Murotani, Y | 1 |
| Kuroda, J | 1 |
| Kimura, S | 1 |
| Terao, K | 1 |
| Fukiya, E | 1 |
| Ozawa, M | 1 |
| Kobayashi, Y | 1 |
| Yoshikawa, T | 1 |
| Nguyen, L | 1 |
| Leger, F | 1 |
| Lennon, S | 1 |
| Puozzo, C | 1 |
| Schuler, U | 1 |
| Schroer, S | 1 |
| Kühnle, A | 1 |
| Blanz, J | 1 |
| Mewes, K | 1 |
| Kumbier, I | 1 |
| Proksch, B | 1 |
| Zeller, KP | 1 |
| Ehninger, G | 1 |
| Gibbs, JP | 1 |
| Gooley, T | 1 |
| Corneau, B | 1 |
| Murray, G | 1 |
| Stewart, P | 1 |
| Appelbaum, FR | 1 |
| Slattery, JT | 1 |
2 reviews available for busulfan and Obesity
| Article | Year |
|---|---|
[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-T
Topics: Adult; Age Factors; Busulfan; Child; Comorbidity; Cyclophosphamide; Etoposide; France; Hematopoietic | 2017 |
Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.
Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Drug Admi | 2014 |
1 trial available for busulfan and Obesity
| Article | Year |
|---|---|
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
Topics: Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Busulfan; Cyclophosphamide; Female; Hema | 2006 |
6 other studies available for busulfan and Obesity
| Article | Year |
|---|---|
Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients.
Topics: Adolescent; Adult; Aged; Body Weight; Busulfan; Disease-Free Survival; Drug Dosage Calculations; Hem | 2019 |
Effectiveness and toxicity of high-dose cyclophosphamide in obese versus non-obese patients receiving allogeneic hematopoietic stem cell transplant.
Topics: Adult; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplant | 2016 |
Busulfan dosing in children with BMIs ≥ 85% undergoing HSCT: a new optimal strategy.
Topics: Adolescent; Area Under Curve; Body Mass Index; Busulfan; Child; Child, Preschool; Drug Dosage Calcul | 2011 |
Non-myeloablative haematopoietic stem cell transplantation for severe aplastic anaemia with various complications.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Female; Fractures, Bone; Graft Rejection; G | 2002 |
Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Drug Monitoring; Eating; Female; He | 1994 |
The impact of obesity and disease on busulfan oral clearance in adults.
Topics: Administration, Oral; Adolescent; Adult; Body Mass Index; Body Surface Area; Body Weight; Busulfan; | 1999 |